Literature DB >> 19443635

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.

Toshiharu Ninomiya1, Vlado Perkovic, Bastiaan E de Galan, Sophia Zoungas, Avinesh Pillai, Meg Jardine, Anushka Patel, Alan Cass, Bruce Neal, Neil Poulter, Carl-Erik Mogensen, Mark Cooper, Michel Marre, Bryan Williams, Pavel Hamet, Giuseppe Mancia, Mark Woodward, Stephen Macmahon, John Chalmers.   

Abstract

There are limited data regarding whether albuminuria and reduced estimated GFR (eGFR) are separate and independent risk factors for cardiovascular and renal events among individuals with type 2 diabetes. The Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study examined the effects of routine BP lowering on adverse outcomes in type 2 diabetes. We investigated the effects of urinary albumin-to-creatinine ratio (UACR) and eGFR on the risk for cardiovascular and renal events in 10,640 patients with available data. During an average 4.3-yr follow-up, 938 (8.8%) patients experienced a cardiovascular event and 107 (1.0%) experienced a renal event. The multivariable-adjusted hazard ratio for cardiovascular events was 2.48 (95% confidence interval 1.74 to 3.52) for every 10-fold increase in baseline UACR and 2.20 (95% confidence interval 1.09 to 4.43) for every halving of baseline eGFR, after adjustment for regression dilution. There was no evidence of interaction between the effects of higher UACR and lower eGFR. Patients with both UACR >300 mg/g and eGFR <60 ml/min per 1.73 m(2) at baseline had a 3.2-fold higher risk for cardiovascular events and a 22.2-fold higher risk for renal events, compared with patients with neither of these risk factors. In conclusion, high albuminuria and low eGFR are independent risk factors for cardiovascular and renal events among patients with type 2 diabetes.

Entities:  

Mesh:

Year:  2009        PMID: 19443635      PMCID: PMC2723977          DOI: 10.1681/ASN.2008121270

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  39 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Imputations of missing values in practice: results from imputations of serum cholesterol in 28 cohort studies.

Authors:  Federica Barzi; Mark Woodward
Journal:  Am J Epidemiol       Date:  2004-07-01       Impact factor: 4.897

3.  Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.

Authors: 
Journal:  J Hypertens Suppl       Date:  2001-11

4.  Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions.

Authors:  M Luiza Caramori; Paola Fioretto; Michael Mauer
Journal:  Diabetes       Date:  2003-04       Impact factor: 9.461

5.  Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

Authors:  Amit X Garg; Bryce A Kiberd; William F Clark; R Brian Haynes; Catherine M Clase
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

6.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

7.  The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region.

Authors:  M Woodward; X Zhang; F Barzi; W Pan; H Ueshima; A Rodgers; S MacMahon
Journal:  Diabetes Care       Date:  2003-02       Impact factor: 19.112

8.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

9.  Assessment and management of hypertension in patients with type 2 diabetes.

Authors:  M C Thomas; R Atkins
Journal:  Intern Med J       Date:  2008-09-02       Impact factor: 2.048

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  294 in total

1.  Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

Authors:  Ian H de Boer; Wanjie Sun; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Bernard Zinman
Journal:  N Engl J Med       Date:  2011-11-12       Impact factor: 91.245

2.  Chronic kidney disease: Albuminuria or CKD stage as best marker of CVD in diabetes?

Authors:  Judith Blaine; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2012-05-29       Impact factor: 28.314

3.  Use of medications to lower urine protein level in patients with diabetic kidney disease.

Authors:  Robert C Stanton
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 4.  Clinical impact of albuminuria in diabetic nephropathy.

Authors:  Takashi Wada; Miho Shimizu; Tadashi Toyama; Akinori Hara; Shuichi Kaneko; Kengo Furuichi
Journal:  Clin Exp Nephrol       Date:  2011-08-10       Impact factor: 2.801

5.  Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.

Authors:  Kouichi Tamura; Hiromichi Wakui; Kengo Azushima; Kazushi Uneda; Satoshi Umemura
Journal:  Hypertens Res       Date:  2016-01-28       Impact factor: 3.872

6.  Microalbuminuria and left ventricular mass in overweight and obese hypertensive patients: role of the metabolic syndrome.

Authors:  Federico Guerra; Lucia Mancinelli; Alessia Buglioni; Valentina Pierini; Alessandro Rappelli; Paolo Dessì-Fulgheri; Riccardo Sarzani
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-12-01

7.  Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.

Authors:  Giuseppe Penno; Anna Solini; Emanuela Orsi; Enzo Bonora; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Olga Lamacchia; Marco Scardapane; Antonio Nicolucci; Giuseppe Pugliese
Journal:  Diabetologia       Date:  2018-07-21       Impact factor: 10.122

Review 8.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

9.  Silent diabetic nephropathy.

Authors:  Katia López-Revuelta; Patricia Peña Galdo; Ramona Stanescu; Leticia Parejo; Carmen Guerrero; Elia Pérez-Fernández
Journal:  World J Nephrol       Date:  2014-02-06

Review 10.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.